コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ion acquired from prior COVID-19 infection ("natural immunity").
2 gainst subsequent genital HPV infection (ie, natural immunity).
3 ine design, as well as provide insights into natural immunity.
4 especially in large populations with little natural immunity.
5 rm persistent antibody responses of acquired natural immunity.
6 nerate more neutralizing RBD antibodies than natural immunity.
7 especially in settings with a high degree of natural immunity.
8 r development is a lack of information about natural immunity.
9 us evolves rapidly to constantly escape from natural immunity.
10 ividuals from 18 countries that examined HPV natural immunity.
11 cation of robust correlates of protection in natural immunity.
12 ite of herpesvirus vulnerability targeted by natural immunity.
13 on, or reinfection with a new strain despite natural immunity.
14 an disease and are moderated by pre-existing natural immunity.
15 ass the level of protection achieved through natural immunity.
16 he epidemic area caused residents to acquire natural immunity.
17 Complement is a component of natural immunity.
18 eisseria meningitidis is believed to lead to natural immunity.
19 own about the extent and mechanisms by which natural immunity acquired during the early COVID-19 pand
23 rtially abrogated the protective efficacy of natural immunity against rechallenge with SARS-CoV-2, wh
25 responses, all of which are associated with natural immunity against Salmonella In vaccinated mice,
26 veloped countries, largely because decreased natural immunity allows for increased susceptibility.
28 Compared to unvaccinated seronegative HCWs, natural immunity and 2 vaccination doses provided simila
29 n of infection, especially in the context of natural immunity and against severe acute respiratory sy
30 lect a broader mechanism that modulates both natural immunity and autoimmunity to other glycotopes.
31 These models allowed us to test the role of natural immunity and cross-protection in determining opt
32 cation of robust correlates of protection in natural immunity and following vaccination against DENV.
33 essential immunologic concepts underpinning natural immunity and highlight the multiple unique chall
34 oorly defined, impeding our understanding of natural immunity and hindering effective vaccine develop
36 lts were most sensitive to assumptions about natural immunity and progression rates after infection,
37 r the viral transmissibility, rate of waning natural immunity and rates of progression and clearance
38 en HIF2alpha, the ITPR1-related pathway, and natural immunity and strongly suggest a role for the HIF
39 study uses serologic testing to characterize natural immunity and the long-term durability of SARS-Co
41 neutralizing serum antibodies in response to natural immunity and vaccination are considered to be ha
44 ion results in robust immunity comparable to natural immunity and vaccine-induced immunity and that t
46 to pessimistic vaccine effectiveness, waning natural immunity, and cross-protection from previous inf
47 s, characterise their clinical syndromes and natural immunity, and evaluate their relevance as causes
48 ression allows little opportunity to develop natural immunity, and there is currently no effective an
49 nts based on vaccination status and level of natural immunity; and (ii) variant- and dose-dependent v
51 s of relevance for understanding patterns of natural immunity, as well as for the development of diag
52 sent a critical component of host defense in natural immunity but also suggest that mast cell functio
53 t the expression of such mast cell-dependent natural immunity can be significantly enhanced by long-t
55 explains the epidemiological observation of natural immunity conferred by carriage of N. lactamica.
57 of emulating the disease-reducing effect of natural immunity could achieve a detectable effect durin
59 ions; 63 respondents [19%] preferred gaining natural immunity), deliberation (74 respondents [22%] pr
60 b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna), natural immunity due to previous infection with variants
61 bjects who control viral load as a result of natural immunity (elite controller [EC]) or with uninfec
64 the protective efficacy conferred by either natural immunity from WA1/2020 infection or by vaccinati
65 ose observed in a population associated with natural immunity.IMPORTANCE The development of effective
67 e a novel immuno-oncology strategy employing natural immunity in the fight against cancers, in partic
68 that may explain the delayed development of natural immunity in the first few years of life and sugg
69 s of cps might be broadly useful to reawaken natural immunity in the highly immunosuppressive microen
71 lation can create a major epidemic wave, but natural immunity in those previously infected was strong
72 tervention aimed at effectively boosting our natural immunity, in the form of a host defensive factor
73 ummarizes what we have learned from acquired natural immunity, including innate and adaptive immunity
74 ased on the original WA1/2020 strain and the natural immunity induced by infection with earlier SARS-
77 artial but incomplete protective efficacy of natural immunity induced by WA1/2020 against SARS-CoV-2
81 This diversity, coupled with short-lasting natural immunity, leads to reinfection throughout one's
82 is a key protective antigen in vaccine- and natural immunity-mediated protection from Bordetella per
83 l risk factor, and population differences in natural immunity need further investigation to understan
88 mains a major cause of global mortality, yet natural immunity prevents disease in more than 90% of ex
90 mmune responses prevented the acquisition of natural immunity similar to that concurrently acquired b
92 ction is mediated initially by components of natural immunity such as xenoreactive antibodies, comple
93 ization rates generate rapid accumulation of natural immunity that alters the indirect effects of vac
94 and parasite genotype-specificity may limit natural immunity, this work serves as a foundation for a
96 ry CD4 TRM cells in immunity to B. pertussis Natural immunity to B. pertussis induced by infection is
97 e safety of IVIg preparations in relation to natural immunity to bacteria and to extend our knowledge
100 we show that CD4(+) T cells are required for natural immunity to Ebola virus infection and that CD4-d
102 Here, we summarize current knowledge in natural immunity to enteric viruses, highlighting specia
104 The data strongly suggest that the lack of natural immunity to hypervirulent GAS strains in humans
105 rgets of immune neutralization in vitro, and natural immunity to infection is associated with serovar
108 s that have occurred in adults suggests that natural immunity to more common strains does not always
109 er, these findings will provide insight into natural immunity to Mtb and will guide development of no
113 matosis, support the concept that there is a natural immunity to primary granule proteins which can b
117 of vaccination, including booster doses, and natural immunity to the infectiousness of individuals wi
118 has largely been achieved in settings where natural immunity to the pathogen results in clearance in
119 s C virus (HCV) infections demonstrated that natural immunity to the virus is induced during primary
121 ersity of, stage-specific expression by, and natural immunity to these two molecules to evaluate thei
126 be substantial effects on chronic pathology, natural immunity, vaccine development strategies, immune
127 d higher mortality resulting from achieving "natural immunity" vs acquiring vaccine-provided immunity
131 he role of complement in mast cell-dependent natural immunity, we examined the responses of complemen
132 -induced immune responses in comparison with natural immunity, we used a panel of broadly neutralizin